David M Griffith1, Steff Lewis2, Adriano G Rossi3, Jillian Rennie3, Lisa Salisbury4, Judith L Merriweather5, Kate Templeton6, Timothy S Walsh1. 1. Department of Anaesthesia, Critical Care and Pain Medicine, University of Edinburgh, Edinburgh, UK MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK Department of Critical Care, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK. 2. Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. 3. MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. 4. School of Health in Social Science, University of Edinburgh, Edinburgh, UK. 5. Department of Critical Care, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK. 6. Department of Medical Microbiology, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Abstract
BACKGROUND: Physical recovery following critical illness is slow, often incomplete and is resistant to rehabilitation interventions. We aimed to explore the contribution of persisting inflammation to recovery, and investigated the potential role of human cytomegalovirus (HCMV) infection in its pathogenesis. METHODS: In an a priori nested inflammatory biomarker study in a post-intensive care unit (ICU) rehabilitation trial (RECOVER; ISRCTN09412438), surviving adult ICU patients ventilated >48 h were enrolled at ICU discharge and blood sampled at ICU discharge (n=184) and 3 month follow-up (N=123). C-reactive protein (CRP), human neutrophil elastase (HNE), interleukin (IL)-1β, IL-6, IL-8, transforming growth factor β1 (TGFβ1) and secretory leucocyte protease inhibitor (SLPI) were measured. HCMV IgG status was determined (previous exposure), and DNA PCR measured among seropositive patients (lytic infection). Physical outcome measures including the Rivermead Mobility Index (RMI) were measured at 3 months. RESULTS: Many patients had persisting inflammation at 3 months (CRP >3 mg/L in 59%; >10 mg/L in 28%), with proinflammatory phenotype (elevated HNE, IL-6, IL-8, SLPI; low TGFβ1). Poorer mobility (RMI) was associated with higher CRP (β=0.13; p<0.01) and HNE (β=0.32; p=0.03), even after adjustment for severity of acute illness and pre-existing co-morbidity (CRP β=0.14; p<0.01; HNE β=0.30; p=0.04). Patients seropositive for HCMV at ICU discharge (63%) had a more proinflammatory phenotype at 3 months than seronegative patients, despite undetectable HMCV by PCR testing. CONCLUSIONS: Inflammation is prevalent after critical illness and is associated with poor physical recovery during the first 3 months post-ICU discharge. Previous HCMV exposure is associated with a proinflammatory phenotype despite the absence of detectable systemic viraemia. TRIAL REGISTRATION NUMBER: ISRCTN09412438, post results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Physical recovery following critical illness is slow, often incomplete and is resistant to rehabilitation interventions. We aimed to explore the contribution of persisting inflammation to recovery, and investigated the potential role of human cytomegalovirus (HCMV) infection in its pathogenesis. METHODS: In an a priori nested inflammatory biomarker study in a post-intensive care unit (ICU) rehabilitation trial (RECOVER; ISRCTN09412438), surviving adult ICU patients ventilated >48 h were enrolled at ICU discharge and blood sampled at ICU discharge (n=184) and 3 month follow-up (N=123). C-reactive protein (CRP), human neutrophil elastase (HNE), interleukin (IL)-1β, IL-6, IL-8, transforming growth factor β1 (TGFβ1) and secretory leucocyte protease inhibitor (SLPI) were measured. HCMV IgG status was determined (previous exposure), and DNA PCR measured among seropositive patients (lytic infection). Physical outcome measures including the Rivermead Mobility Index (RMI) were measured at 3 months. RESULTS: Many patients had persisting inflammation at 3 months (CRP >3 mg/L in 59%; >10 mg/L in 28%), with proinflammatory phenotype (elevated HNE, IL-6, IL-8, SLPI; low TGFβ1). Poorer mobility (RMI) was associated with higher CRP (β=0.13; p<0.01) and HNE (β=0.32; p=0.03), even after adjustment for severity of acute illness and pre-existing co-morbidity (CRP β=0.14; p<0.01; HNE β=0.30; p=0.04). Patients seropositive for HCMV at ICU discharge (63%) had a more proinflammatory phenotype at 3 months than seronegative patients, despite undetectable HMCV by PCR testing. CONCLUSIONS: Inflammation is prevalent after critical illness and is associated with poor physical recovery during the first 3 months post-ICU discharge. Previous HCMV exposure is associated with a proinflammatory phenotype despite the absence of detectable systemic viraemia. TRIAL REGISTRATION NUMBER: ISRCTN09412438, post results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Matthew R Baldwin; Lauren R Pollack; Richard A Friedman; Simone P Norris; Azka Javaid; Max R O'Donnell; Matthew J Cummings; Dale M Needham; Elizabeth Colantuoni; Mathew S Maurer; David J Lederer Journal: Thorax Date: 2020-12-09 Impact factor: 9.139
Authors: Catherine Madurski; Jessica M Jarvis; Sue R Beers; Amy J Houtrow; Amy K Wagner; Anthony Fabio; Chunyan Wang; Craig M Smith; Lesley Doughty; Keri Janesko-Feldman; Pamela Rubin; Dorothy Pollon; Amery Treble-Barna; Patrick M Kochanek; Ericka L Fink Journal: Neurocrit Care Date: 2021-03-04 Impact factor: 3.532
Authors: M E Major; R Kwakman; M E Kho; B Connolly; D McWilliams; L Denehy; S Hanekom; S Patman; R Gosselink; C Jones; F Nollet; D M Needham; R H H Engelbert; M van der Schaaf Journal: Crit Care Date: 2016-10-29 Impact factor: 9.097
Authors: Elie Azoulay; Jean-Louis Vincent; Derek C Angus; Yaseen M Arabi; Laurent Brochard; Stephen J Brett; Giuseppe Citerio; Deborah J Cook; Jared Randall Curtis; Claudia C Dos Santos; E Wesley Ely; Jesse Hall; Scott D Halpern; Nicholas Hart; Ramona O Hopkins; Theodore J Iwashyna; Samir Jaber; Nicola Latronico; Sangeeta Mehta; Dale M Needham; Judith Nelson; Kathleen Puntillo; Michael Quintel; Kathy Rowan; Gordon Rubenfeld; Greet Van den Berghe; Johannes Van der Hoeven; Hannah Wunsch; Margaret Herridge Journal: Crit Care Date: 2017-12-05 Impact factor: 9.097
Authors: Nicholas J Cowley; Andrew Owen; Sarah C Shiels; Joanne Millar; Rebecca Woolley; Natalie Ives; Husam Osman; Paul Moss; Julian F Bion Journal: JAMA Intern Med Date: 2017-06-01 Impact factor: 21.873